<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From June 1990 to February 1996, 35 patients with B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) 13 of whom had <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease and 28 patients with stage IV B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) 22 of whom had <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement were treated with a short, intensive multiagent chemotherapy regimen (UKCCSG 9003 protocol) based on the French LMB 86 regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-five were boys </plain></SENT>
<SENT sid="2" pm="."><plain>The age range was 11 months to 16.5 years (median 8.4 years) </plain></SENT>
<SENT sid="3" pm="."><plain>Chemotherapy included <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (COPADM) and <z:chebi fb="0" ids="4911">etoposide</z:chebi>/high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (CYVE) with frequent intrathecal (i.t.) triple therapy (<z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>Cranial irradiation (24 Gy in 15 fractions) was recommended in patients with overt <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease </plain></SENT>
<SENT sid="5" pm="."><plain>One patient with <z:e sem="disease" ids="C0043194" disease_type="Disease or Syndrome" abbrv="">Wiskott-Aldrich syndrome</z:e> was withdrawn after entry and has been excluded from the analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Ten patients (16%) have relapsed (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>, four; BM, two; combined <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> and BM, three; and jaw, one) 4-11 months after diagnosis and two patients never achieved complete remission (CR) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> have died </plain></SENT>
<SENT sid="8" pm="."><plain>In seven of the patients who relapsed, treatment had been modified or delayed because of poor clinical condition </plain></SENT>
<SENT sid="9" pm="."><plain>Seven patients (11%) died of toxicity 11 days to 4 months after diagnosis </plain></SENT>
<SENT sid="10" pm="."><plain>The cause of <z:hpo ids='HP_0011420'>death</z:hpo> was <z:hpo ids='HP_0100806'>sepsis</z:hpo> (n = 5) or <z:hpo ids='HP_0100806'>sepsis</z:hpo> with <z:hpo ids='HP_0000083'>renal failure</z:hpo> (n = 2) </plain></SENT>
<SENT sid="11" pm="."><plain>With a median follow-up of 3.1 years from diagnosis (range 9 months to 6.3 years), 43 patients (69%) survive in CR </plain></SENT>
<SENT sid="12" pm="."><plain>This study confirms the effectiveness of this regimen with regard to the relapse rate (16%), although the rate of toxic <z:hpo ids='HP_0011420'>death</z:hpo> is of concern </plain></SENT>
</text></document>